Effect of Levocarnitine on Contrast-induced Nephropathy in Coronary Artery Disease Patients After Percutaneous Coronary Intervention
10.3969/j.issn.1000-3614.2016.02.004
- VernacularTitle:左卡尼汀对于冠状动脉介入治疗后对比剂肾病的影响
- Author:
Haifeng ZHANG
- Publication Type:Journal Article
- Keywords:
Levocarnitine;
Angiography;
Contrast-induced nephropathy
- From:
Chinese Circulation Journal
2016;31(2):116-118
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To investigate the effect of levocarnitine on contrast-induced nephropathy (CIN) in coronary artery disease (CAD) patients after percutaneous coronary intervention (PCI).
Methods: A total of 138 CAD patients with PCI were studied. Upon basic hydration, the patients were divided into 2 groups:Levocarnitine group, the patients received intravenous infusion of levocarnitine 2g at 24h before PCI and levocarnitine 2g/day after PCI for 4 days and Non-levocarnitine group. n=69 in each group. Blood levels of urea nitrogen (BUN), creatinine (Scr), creatinine clearance rate (Ccr) and the occurrence rate of CIN were compared between 2 groups at 24h and 72h after PCI. All contrast agent used in the operation was Ultravist non ionic low permeability contrast solution and the dosage was recorded during operation.
Results: Compared with Non-levocarnitine group, Levocarnitine group had decreased blood levels of BUN and Scr at 24h and 72h after operation;increased post-operative Ccr, all P<0.05;the occurrence rate of CIN in Levocarnitine group was lower than Non-levocarnitine group (5.80%vs 15.94%), P<0.05.
Conclusion: Application of levocarnitine has certain preventive and protective effect for CIN occurrence in CAD patients after PCI.
